CYNBIOSE AND VIRNEXT CONGRATULATE THE PHARMACEUTICAL COMPANY HIPRA UPON COVID-19 VACCINE’S, BIMERVAX®, APPROVAL BY THE EUROPEAN MEDICINES AGENCY (EMA)
Lyon, France, April 25th, 2023 – CYNBIOSE, a service company specializing in the development of innovative preclinical models, in partnership with VIRNEXT, a technological platform specializing in respiratory infectious diseases and evaluation of prophylactic and therapeutic treatments, have contributed actively to the preclinical assessment and accelerated transfer to clinical trial of HIPRA’s Covid-19 vaccine. At the time the SARS-CoV-2 pandemic was at its peak, HIPRA, a biotechnological pharmaceutical company, initiated a preclinical evaluation of its vaccine candidate to confirm its safety and efficacy in a translational model.
The active component of the HIPRA Covid-19 vaccine is an heterologous recombinant heterodimer protein that emulates the receptor binding domain (RBD) of the Spike (S) protein of the Alpha and Beta variants of the SARS-Cov-2 virus. The antigen, which is the active component of the vaccine, requires an adjuvant to amplify and enhance the immune response.
The preclinical trials were completed in 2021. The European Commission announced in August 2022 it had signed a pre-purchase agreement with HIPRA to supply its Covid-19 vaccine, subject to approval by the European Medicines Agency (EMA). The agreement involves 13 countries and should allow the purchase of up to 250 million doses, said the European executive in a statement1.
CYNBIOSE and VIRNEXT were selected to perform the preclinical studies in a SARS-CoV-2 large animal efficacy model. To know more
